《你好，星期六》是湖南卫视重点打造的周六黄金档棚内周播趣味艺能综艺秀。节目重点围绕艺人艺能的全面深度挖掘、流光溢彩的精品表演秀的创意呈现、最具热点的社会性话题输出等方面进行设计。全面展现嘉宾的专业素养，重新定义了以艺服人、以能动人的综艺准入门槛。

HI-6 has consistently been the most effective reactivator of soman-inhibited AChE when tested in a variety of animal models (blood and tissue), and humans (blood) compared to other oximes, including the currently developed pralidoxime (2-PAM) and obidoxime (Koplovitz and Stewart, 1994; Shih, 1993; Worek et al., 1998; Puu et al., 1986).

Asoxime chloride, or more commonly HI-6, is a Hagedorn oxime used in the treatment of organophosphate poisoning. [1]

2019年5月9日 · After half a century of extensive military medical research and development for the Bundeswehr HI 6 - DMS is a relatively new development in the field of oximes, representing a further step towards an improved therapy of nerve agent poisoning.

2024年1月1日 · HI-6 DMS is the proposed oxime replacement for P2S in the triple therapy nerve agent medical countermeasure and it is, therefore, necessary to provide evidence to demonstrate its efficacy and to compare it to both HI-6 Cl2 and P2S in support of its future licensing.

2018年9月1日 · Here, it has been demonstrated that intravenous infusion of HI-6, in combination with atropine, is efficacious against a percutaneous VX challenge in the conscious male Dunkin-Hartley guinea-pig. Inclusion of HI-6, in addition to atropine in the treatment, improved survival when compared to atropine alone.

Asoxime (HI-6) is a well known oxime reactivator used for counteracting intoxication by nerve agents. It is able to reactivate acetylcholinesterase (AChE) inhibited even by sarin or soman. The present experiment was aimed to determine markers of oxidative stress represented

HI-6 is one of the most promising reactivators which is effective in reactivating AChE inhibited by many nerve agents. However, the fast in-vivo clearance of HI-6 became a large barrier for first aid use under some sophisticated circumstances. In this study, PEGylated liposomes loading HI-6 were prepared and evaluated in vitro and in vivo.

The bispyridinium oxime HI-6 DMS is in development as an improved therapy for the treatment of patients exposed to organophosphorus nerve agents. The aim of the work described in this paper was to provide non-clinical data to support regulatory approval of HI-6 DMS, by demonstrating efficacy against …

Support for brain-targeting potency came from imaging results. Notably, intravenous injection of HI-6-loaded vesicles exhibited a remarkable therapeutic effect on paraoxon (POX)-poisoned mice, effectively alleviating seizures and brain damage and significantly increasing the improving survival rate to 60% over the course of 7 days.